Halozyme Therapeutics (NASDAQ:HALO) Cut to Hold (C+) at Weiss Ratings

Weiss Ratings downgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy (b-) rating to a hold (c+) rating in a research note released on Saturday,Weiss Ratings reports.

A number of other equities analysts also recently commented on the stock. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price on the stock. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, October 21st. Four investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $73.11.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $65.85 on Friday. The company’s fifty day simple moving average is $71.64 and its 200-day simple moving average is $62.39. Halozyme Therapeutics has a 52 week low of $42.01 and a 52 week high of $79.50. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The company has a market cap of $7.70 billion, a PE ratio of 15.07, a P/E/G ratio of 0.35 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter last year, the firm posted $0.91 EPS. The business’s revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Buying and Selling

In other news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total value of $150,480.00. Following the completion of the sale, the director owned 44,952 shares of the company’s stock, valued at approximately $3,382,188.48. The trade was a 4.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $50,648,622.57. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,227 shares of company stock valued at $7,779,595 in the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Campbell Newman Asset Management Inc. increased its position in shares of Halozyme Therapeutics by 0.4% in the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after purchasing an additional 153 shares during the last quarter. Isthmus Partners LLC increased its position in shares of Halozyme Therapeutics by 2.5% in the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock worth $439,000 after purchasing an additional 169 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the last quarter. OneDigital Investment Advisors LLC increased its position in shares of Halozyme Therapeutics by 1.7% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 175 shares during the last quarter. Finally, Park Place Capital Corp grew its position in shares of Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 182 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.